stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) EPS (diluted)
QIAGEN N.V.'s EPS (diluted) for fiscal 2025 was $1.94, up 424.3% from $0.37 in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.95. Over the past ten years it has ranged from −$0.20 (fiscal 2019) to $2.47 (fiscal 2021); the current reading is higher than 82% of that period. QIAGEN N.V. ranks 16th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.94 | 424.32% |
| FY2024 | $0.37 | (75.00%) |
| FY2023 | $1.48 | (27.94%) |
| FY2022 | $2.05 | (16.74%) |
| FY2021 | $2.47 | 44.44% |
| FY2020 | $1.71 | — |
| FY2019 | −$0.20 | — |
| FY2018 | $0.92 | 382.24% |
| FY2017 | $0.19 | (49.99%) |
| FY2016 | $0.38 | (39.37%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.50 | 51.52% |
| Mar 2026 | $0.33 | (32.65%) |
| Dec 2025 | $0.49 | (22.42%) |
| Sep 2025 | $0.63 | 36.36% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MEDP Medpace Holdings, Inc. compare | $18.04 |
| ICLR ICON PLC compare | $5.81 |
| RVTY Revvity Inc. compare | $2.26 |
| QGEN QIAGEN N.V. | $1.95 |
| CRL Charles River Laboratories International, Inc. compare | $0.93 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| RDNT RadNet, Inc. compare | −$0.27 |
| GH Guardant Health, Inc. compare | −$3.68 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on QGEN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement